Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
| Image |  |
|---|---|
| Description | scientific article published on 26 September 2019 |
| Author/s |
author: Mark G. Lebwohl |
| Publication date | September 26, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |